Skip to content

Canadian Journal of Health Technologies

ISSN 2563-6596

3 papers in the library · 9 citations · publishing 2021-2024

Papers

Sort Most recent Most cited

Ketamine for Adults With Treatment-Resistant Depression or Posttraumatic Stress Disorder: A 2023 Update

Canadian Journal of Health Technologies January 17, 2024 Angela M. Barbara, Weiyi Xie, Quenby Mahood et al. 4 citations

What Is the Issue? Many drug treatments are available for depression, but 22% of people in Canada with the condition have treatment-resistant depression (TRD). For people with TRD, standard drug treatments do not improve their symptoms or do not work for long, and their depression persists. Posttraumatic stress disorder (PTSD) is a disabling mental health condition that affects about 9% of...

Ketamine for Adults With Treatment-Resistant Depression or Post-Traumatic Stress Disorder

Canadian Journal of Health Technologies April 12, 2022 Khai Tran, Quenby Mahood

Two randomized controlled trials reported mixed evidence on the efficacy of repeated IV ketamine infusions for improving post-traumatic stress disorder. One randomized controlled trial with small sample size found that repeated IV ketamine infusions significantly improved post-traumatic stress disorder symptoms compared with midazolam in civilian population, while the other randomized...

Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders

Canadian Journal of Health Technologies June 24, 2021 Yi‐sheng Chao, Jennifer Horton 5 citations

Two systematic reviews, 3 randomized controlled trials, and 2 single-arm safety trials were identified that evaluated several combinations of psychedelic-assisted psychotherapy. Psilocybin was the psychedelic most tested. Other psychedelics identified in the systematic reviews and primary studies were 3,4-methylenedioxymethamphetamine (or MDMA), lysergic acid diethylamide (or LSD), ayahuasca...